^○Youwei Lin^1,2, Wakiro Sato², Tomoko Okamoto¹, Takashi Yamamura², Yuji Takahashi¹ (1.Dep.Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Japan, 2.Dep.Immunology, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Japan)

^○Yusei Miyazaki¹, Masaaki Niino², Hiroaki Yokote³, Eri Takahashi², Kei Oiwa¹, Ryouji Naganuma¹, Itaru Amino¹, Sachiko Akimoto¹, Naoya Minami¹, Seiji Kikuchi¹ (1.Department of Neurology, Hokkaido Medical Center, Japan, 2.Department of Clinical Research, Hokkaido Medical Center, 3.Department of Neurology, Nitobe Memorial Nakano General Hospital)

^○Takahiko Saida^1,2,3, Qi Hao^1,2,3, Michiko Yamauchi^1,2, Kyoko Saida^1,2,3 (1.Kansai Multiple Sclerosis Center, Japan, 2.Kyoto Neurology Clinic, Institute for Multiple Sclerosis Therapeutics, Japan, 3.Irino Clinic Kansai Multiple Sclerosis Center, Japan)

^○Masashi Nakamura¹, Ryo Ogawa¹, Juichi Fujimori¹, Akiyuki Uzawa², Yasunori Sato³, Kengo Nagashima⁴, Nagato Kuriyama^5,6, Satoshi Kuwabara², Ichiro Nakashima¹ (1.Division of Neurology, Tohoku Medical and Pharmaceutical University, Japan, 2.Department of Neurology, Graduate School of Medicine, Chiba University, 3.Department of Preventive Medicine and Public Health, School of Medicine, Keio University, 4.Clinical and Translational Research Center, Keio University, 5.Department of Social Health Medicine, Shizuoka Graduate University of Public Health, 6.Departments of Epidemiology for Community Health and Medicine, Kyoto Prefectural University of Medicine)